Rare but serious gastrointestinal complications have been reported in post-marketing surveillance, including: Acute pancreatitis : If suspected, the GLP-1 agonist should be stopped immediately and not restarted if pancreatitis is confirmed Severe gastroparesis : Rare post-marketing reports of severe delayed gastric emptying Intestinal obstruction : Very rare cases reported in post-marketing surveillance Patients should be advised to seek urgent medical help via NHS 111, A&E or 999 as appropriate if they experience severe or persistent abdominal pain, persistent vomiting, abdominal distension, inability to pass stool or gas, or bloody diarrhoea whilst taking GLP-1 agonists
It is important to note that this mechanism, while biologically plausible, is not yet validated by large-scale controlled trials, and individual results vary considerably depending on baseline melanin levels, skin type, and dosage
del Pinal F, Garcia-Bernal FJ, Regalado J, Studer A, Ayala H, Cagigal L
Take medication at the first sign of a headache rather than waiting for pain to intensify
Curious if weight loss medication could be part of your sleep apnea journey
If you are asking Is Tirzepatide the Same as Mounjaro, this post lays out the facts about brand name versus generic, how the drug works through GIP and GLP 1 pathways, what clinical trials show for weight loss, and the common side effects so you can compare efficacy, dosing and safety
